Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹684.9 Cr
verified against source
Revenue YoY
18%
reported change
EBITDA
₹77.3 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Rossari Biotech delivered a strong Q4 FY26 with revenue of ₹684.9 crore (+18% YoY) and EBITDA of ₹77.3 crore (+11% YoY), marking the highest-ever quarterly revenue and EBITDA. Growth was broad-based across all three segments (HPCC +20%, Textiles +10%, AHN +11%), driven by volume and customer engagement. EBITDA margin contracted 70 bps YoY to 11.3% due to raw material cost spikes (25-30% for some inputs) and a less favorable sales mix. Management guided for at least 15% revenue growth in FY27 and EBITDA margins of 12-13%, supported by new ethoxylation capacity, pharma/agro/oil & gas expansion, and cost optimization. Risks include geopolitical uncertainty in the Middle East and potential demand softness from El Niño.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects minimum 15% revenue growth in FY27, similar to FY26, with potential upside if global conditions improve.
- EBITDA margin expected to remain at current levels of 12-13% for FY27, with improvement from pharma and cost initiatives in H2.
- Capital expenditure for FY27 planned at ₹50-75 crore, focused on Saudi facility and aroma chemicals.
- Management aims to significantly reduce debt and become debt-free within 18 months through cash flows and non-core asset sales.
Risks flagged
- Ongoing conflict in the Middle East could disrupt supply chains, logistics, and demand, impacting near-term performance.
- March saw raw material price increases of 25-30%, which impacted gross margins; pass-through is ongoing but may face resistance in textiles.
- El Niño could affect the agro season and demand for agrochemicals, though management says it's too early to comment.
- The Saudi initiative is a key strategic step but faces uncertainties from geopolitical developments and may take time to ramp up.
Key quotes
- We concluded the year 26 on a very strong note with Q4 marking our highest ever quarterly revenue and AIDA performance for the full year.
- Our focus remains on strengthening customer relationships, expanding the product market, improving market penetration, and building scale in relevant chemistries and applications.
- The target is to actually get debt free by in the next 18 months but I think that the time is there but currently the plan is to keep bringing down our debts over the next 18 months.
Research modules